Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lonza Completes Expansion of Conjugation Facility in Visp | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lonza Completes Expansion of Conjugation Facility in Visp

Adds development and manufacturing capacity for preclinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lonza, a partner to the pharmaceutical, biotech and nutraceutical markets, has completed a planned expansion of its bioconjugation facility in Visp, Switzerland.
 
The expansion includes two manufacturing suites and supporting infrastructure to support an extended customer portfolio, including companies entering clinical development. The investment enhances capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates. 
 
Lonza also recently invested in expanding mammalian capacity, microbial development, drug product development and manufacturing, and HPAPI payload-linker manufacturing capacity in Visp. These continued investments into the Visp (CH) site aim to help customers navigate the risks of a complex bioconjugation supply chain. In addition to the two new manufacturing suites, the expansion also includes an increase in process and analytical development and quality control capacity to support future portfolio growth.
 
Stefan Egli, Vice President, Head of Bioconjugates, Lonza, said, “The opening of the new bioconjugate manufacturing suites in Visp (CH) reflects our dedication to continuously improving our offering and expertise in line with anticipated market and customer needs. Combined with our offerings across drug substance and drug product manufacturing in small molecules and biologics, our bioconjugation services can support projects from early phase through to late-stage and commercial programs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics